ten of 18 ( 56 percent ) patients with hemophilia a who were frequently treated with commercial factor viii concentrate were seropositive for lav/htlv-iii antibodies as determined by immunofluorescent study and western blot testing .
C0019069
hemophilia a
C0015506
factor viii